NEW YORK and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and Jan Torleif... Read More

Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression,... Read More

BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) Findings highlight BMB-101’s potential to address critical gaps in SUDEP prevention NEW YORK and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a... Read More

VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am –... Read More

Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research to support Company’s clinical focus on epilepsy VANCOUVER, British Columbia, March 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a pioneering company... Read More

NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and select members of... Read More

Dr. Collins brings extensive drug development and clinical expertise in epilepsy NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc . (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders,... Read More

Poster presentations on BMB-101 will focus on 5-HT 2C functional selectivity and Phase 1 clinical data NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, is proud to announce two upcoming presentations at... Read More

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company (“ Shares ”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000... Read More

NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing... Read More

VANCOUVER, British Columbia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) is pleased to announce a non-brokered private placement of common shares in the capital of the Company (“ Shares ”) at a price of USD$21.70 per Share (the “ Share Offering ”). In addition to the Shares issued under the Share Offering, the Company reserves the right to... Read More

BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data from the... Read More

TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced collaborating with Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company... Read More

Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (" Bright Minds " or the " Company ") wishes to confirm that the Company's management is unaware of any material changes in the Company's operations that would account for the recent increase in market activity. About Bright Minds Bright Minds is focused on developing novel... Read More

Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnering event and Chicago Biocapital Summit to present its innovation in neuroscience NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly... Read More

Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on September 25th. The event will feature Epilepsy KOLs to discuss the unmet needs for epilepsy treatment. BMB-101 is the first 5-HT2C agonist in clinical studies designed to exclusively target therapeutic pathways (via G-protein)... Read More

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist. Its G-protein biased agonism provides an improved mechanism of action for chronic dosing Financial runway extending into 2026 enabling key data readout Conference call & KOL Event – will be held as a webcast on September 25th at... Read More

VANCOUVER, BC , Dec. 6, 2023 /CNW/ - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company"), a leading biotechnology company specializing in the development of novel treatments for neuropsychiatric disorders, epilepsy, and pain, is excited to announce a fully management-subscribed, non-brokered private placement. This placement involves up to 661,765 units of the Company (the "Units") at a... Read More

BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study Proof of Mechanism and target engagement in the brain was established using blood biomarkers and qEEG In qEEG, BMB-101... Read More

BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending dose and food effects study -BMB-101 demonstrated central target engagement and predictable plasma pharmacokinetics... Read More

VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that, further to its news release on June 22, 2023, the Company will consolidate its common shares (the “ Common Shares ”)... Read More

VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that it intends to consolidate its common shares (the “ Common Shares ”) on a five (5) to one (1) basis (the “... Read More

BMB-202 is a highly selective 5-HT 2A agonist that exhibits a more than 30-fold selectivity over 5-HT 2C and more than 500-fold selectivity over 5-HT 2B BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT 2A and 5-HT 2A/2C agonists inspired from natural compound scaffolds VANCOUVER, British Columbia, April 19, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“... Read More

Presentation entitled "BMB-101: A selective 5-HT 2C agonist in clinical trials with therapeutic utility" First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia VANCOUVER, British Columbia, April 10, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment... Read More

First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT 2C agonist, is underway in Australia Company has transitioned from a discovery to a development organization Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “... Read More

VANCOUVER, British Columbia, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment to its board of directors (the “ Board ”) of David Weiner, MD, as a non-executive director. The... Read More

VANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”) announces that it has received a letter (the “ Deficiency Letter ”) from the Nasdaq Stock Market LLC (“ NASDAQ ”) dated February 2, 2023, stating that following the resignation of Dr. Williamson from the Company’s board of directors and audit committee, the Company no... Read More

VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”) announces that it has received a notification letter (the “ Notification Letter ”) from the Nasdaq Stock Market LLC (“ NASDAQ ”) dated January 26, 2023, notifying the Company that due to thirty consecutive business days of closing bid prices for the common shares in the... Read More

VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role... Read More

Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain,... Read More